Proteomics International Laboratories

Proteomics International Laboratories FCF Margin

The Free Cash Flow Margin of Proteomics International Laboratories (PIQ.AX) as of Oct 28, 2026 is -2,835.17 %. In the previous year, Free Cash Flow Margin was -690.76 % — a change of 310.44% (lower).

FCF Margin

-2,835.17 %

YoY

310.44%

Last updated:

Free Cash Flow Margin of Proteomics International Laboratories is 2026 -2,835.17 % . Free Cash Flow Margin of Proteomics International Laboratories was 2025 -690.76 % . It decreases by 310.44% lower compared to the previous year.

The Proteomics International Laboratories FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2019
-116.14 AUD
Jan 1, 2020
-138.48 AUD
Jan 1, 2021
-184.18 AUD
Jan 1, 2022
-246.38 AUD
Jan 1, 2023
-946.25 AUD
Jan 1, 2024
-672.13 AUD
Jan 1, 2025
-690.76 AUD
Jan 1, 2026
-2,835.17 AUD
The Proteomics International Laboratories FCF Margin history
YEARFCF MarginYoY
-2,835.17 %+310.44%
-690.76 %+2.77%
-672.13 %-28.97%
-946.25 %+284.06%
-246.38 %+33.77%
-184.18 %+33.00%
-138.48 %+19.24%
-116.14 %+20.45%
-96.42 %-44.85%
-174.83 %-6.25%
-186.49 %+64.11%
-113.64 %+277.23%
-30.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Proteomics International Laboratories Stock analysis

What does Proteomics International Laboratories do? Proteomics International Laboratories Ltd is a medical technology company based in Nedlands, Western Australia, listed on the stock exchange in April 2015. Operating within the health care sector, the firm specializes in predictive diagnostics and bio-analytical services, focusing on the study of protein structure and function. It develops and commercializes diagnostic tests for chronic diseases, particularly diabetic kidney disease. The company operates three unified business units: PromarkerD, which offers a blood test to assess DKD risk in type 2 diabetes patients; Diagnostics, which utilizes the Promarker platform to discover and validate protein biomarkers; and Analytical Services, which employs a proteomics-based technology platform to test and validate the protein composition of various products. Proteomics International Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proteomics International Laboratories stock

Free Cash Flow Margin of Proteomics International Laboratories is -2,835.17 % in 2026.

Free Cash Flow Margin of Proteomics International Laboratories changed from -690.76 % to -2,835.17 %, representing a 310.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Proteomics International Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Proteomics International Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Proteomics International Laboratories

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Proteomics International Laboratories